Cutibacterium Strain Composition for Inflammation and Pathogen Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for inflammatory skin diseases, such as acne and rosacea, are inadequate in effectively inhibiting skin pathogens and do not address the secondary infections caused by skin barrier damage from UV exposure without side effects.
Innovation Solution
A Cutibacterium sp. strain, including an Lrp/AsnC family transcriptional regulator and a lactococcin 972 family bacteriocin, is used to develop compositions for preventing, alleviating, and treating inflammatory skin diseases through anti-inflammatory, antibacterial, and skin-regenerative activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for inflammatory skin diseases are used, then some therapeutic effect is achieved, but they fail to effectively inhibit skin pathogens and cause side effects
Solution Approach 1:
The patent utilizes Cutibacterium sp. strain, a bacterium that naturally inhabits human skin, to treat inflammatory skin diseases. By converting a commensal organism into a therapeutic agent, the invention achieves pathogen inhibition without introducing harmful foreign substances, thus eliminating side effects while improving reliability of pathogen inhibition
Solution Approach 2:
The Cutibacterium sp. strain acts as an intermediary between the skin's natural environment and the therapeutic goal. It produces bacteriocins and other substances that mediate the inhibition of pathogenic bacteria, providing a bridge between natural skin flora and disease treatment without direct use of harmful chemicals
2Reliability
If conventional treatments are applied, then inflammation is addressed, but secondary infections from skin barrier damage are not prevented
Solution Approach 1:
The Cutibacterium sp. strain performs multiple functions simultaneously: it inhibits pathogenic bacteria through bacteriocin production, reduces inflammation through anti-inflammatory substances, and promotes skin barrier recovery. This multi-functionality provides comprehensive protection against secondary infections while maintaining adaptability to different skin conditions
Solution Approach 2:
The therapeutic strain utilizes the skin's natural environment and resources to produce protective substances. It self-regulates its bacteriocin production and anti-inflammatory response based on the local microbial and inflammatory conditions, providing adaptive protection without requiring external intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Cutibacterium sp. strain compositions demonstrate non-cytotoxicity, inhibit immune cell proliferation, reduce inflammatory markers, and promote skin regeneration, providing effective prevention and treatment of inflammatory skin diseases.
Implementation Method 1
a lactococcin 972 family bacteriocin or a gene encoding the same
Implementation Method 2
effects on preventing, alleviating and/or treating inflammatory skin disease
Implementation Method 3
promote skin regeneration
Data Source
AI summary
The present application relates to a use of a Cutibacterium sp. strain, a culture product of the strain or a combination thereof for preventing, alleviating and/or treating inflammatory skin disease. A composition comprising the Cutibacterium sp. strain, the culture product of the strain or the combination thereof is non-cytotoxic, inhibits the proliferation of immune cells that induce skin inflammation, inhibits an immune response, has anti-bacterial effects on acne-causing bacteria, and promotes the regeneration of skin cells, and thus has the excellent effects of preventing, alleviating and/or treating inflammatory skin disease.